In last trading session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE) saw 0.54 million shares changing hands with its beta currently measuring 1.31. Company’s recent per share price level of $6.27 trading at $0.06 or 0.97% at ring of the bell on the day assigns it a market valuation of $385.21M. That closing price of GLUE’s stock is at a discount of -97.77% from its 52-week high price of $12.40 and is indicating a premium of 48.8% from its 52-week low price of $3.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.63 million shares which gives us an average trading volume of 801.17K if we extend that period to 3-months.
For Monte Rosa Therapeutics Inc (GLUE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.03 in the current quarter.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Upright in the green during last session for gaining 0.97%, in the last five days GLUE remained trading in the red while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $6.27 price level, adding 6.42% to its value on the day. Monte Rosa Therapeutics Inc’s shares saw a change of -9.65% in year-to-date performance and have moved -1.88% in past 5-day. Monte Rosa Therapeutics Inc (NASDAQ:GLUE) showed a performance of -0.63% in past 30-days. Number of shares sold short was 8.04 million shares which calculate 17.6 days to cover the short interests.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 51.19M for the same. And 5 analysts are in estimates of company making revenue of 5.88M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -96.71% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 57.02% while estimates for its earnings growth in next 5 years are of 9.42%.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Insiders are in possession of 0.70% of company’s total shares while institution are holding 102.42 percent of that, with stock having share float percentage of 103.14%. Investors also watch the number of corporate investors in a company very closely, which is 102.42% institutions for Monte Rosa Therapeutics Inc that are currently holding shares of the company. NEA MANAGEMENT COMPANY, LLC is the top institutional holder at GLUE for having 7.69 million shares of worth $28.77 million. And as of 2024-06-30, it was holding 10.7986 of the company’s outstanding shares.
The second largest institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, which was holding about 5.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.9368 of outstanding shares, having a total worth of $22.36 million.
On the other hand, Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.4 shares of worth $21.34 million or 5.54% of the total outstanding shares. The later fund manager was in possession of 1.92 shares on Dec 31, 2024 , making its stake of worth around $12.05 million in the company or a holder of 3.13% of company’s stock.
